AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21930328
Drug: Ustekinumab 45
RxNorm normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 45 mg (ACCEPT trial)
Trial: 21930328
Drug: Ustekinumab 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 90 mg (ACCEPT trial)
Trial: 7549411
Drug: Caffeine (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3.5 mg/kg in 200 ml)
Trial: 7549411
Drug: Alcohol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.5 g/kg made up to 200 ml)
Trial: 26731113
Drug: Promitor™ Soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promitor™ Soluble Corn Fibre (SCF) at 6 g/fibre/day
Trial: 26731113
Drug: Promitor™ Soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promitor™ Soluble Corn Fibre (SCF) at 12 g/fibre/day
Trial: 26731113
Drug: Promitor™ Soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promitor™ Soluble Corn Fibre (SCF) at 18 g/fibre/day
Trial: 15650986
Drug: Morphine HCl
RxNorm normalized name: morphine HCl
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine HCl (1 mg/mL) with an infusion rate of 0.3 mg/h and 1‐mg bolus doses
Trial: 15650986
Drug: Fentanyl (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (50 microg/mL) with an infusion rate of 1 microg/kg/h and 10‐microg bolus
Trial: 15650986
Drug: Remifentanil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (50 microg/mL) with an infusion rate of 0.05 microg/kg/min and 0.5‐microg/kg bolus
Trial: 8150634
Drug: Systemic venous
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic venous infusions (SVI) with netilmycin, three times/day for 10 days
Trial: 29373242
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) cream 0.05%
Trial: 27197727
Drug: Transmeatal low‐level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmeatal low‐level laser therapy for tinnitus
Trial: 18312937
Drug: Intracavernosal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal saline infusion
Trial: 16151336
Drug: Etanercept (ETA)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETA) 25 mg SC twice weekly for 8 weeks
Trial: 10490438
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg triptorelin intramuscularly every four weeks (group 1)
Trial: 8628471
Drug: Coagulant or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coagulant or antiaggregant therapy, surgical closure of PFO
Trial: 8628471
Drug: Treatment type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment type (coagulant or antiaggregant therapy, surgical closure of PFO)
Trial: 3524513
Drug: Clinic treatment
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic treatment by a speech pathologist for 12 weeks, followed by 12 weeks of no treatment
Trial: 3524513
Drug: Home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home treatment by a trained volunteer for 12 weeks, followed by 12 weeks of no treatment
Trial: 3524513
Drug: Deferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred treatment for 12 weeks, followed by 12 weeks of treatment by a speech pathologist
Trial: 19508159
Drug: High-dose (HD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (HD) trivalent, inactivated influenza vaccine (60 microg of hemagglutinin per strain)
Trial: 19508159
Drug: Standard-dose (SD)
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose (SD) trivalent, inactivated influenza vaccine (15 microg of hemagglutinin per strain)
Trial: 19508159
Drug: High-dose (HD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (HD) trivalent, inactivated influenza vaccine
Trial: 16817038
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of dialysis treatment.
Trial: 10688090
Drug: Placebo 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.20 g
Trial: 21332937
Drug: Four-times faster
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-times faster infusion rate delivery (FIRD)
Trial: 21332937
Drug: Slower infusion
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slower infusion rate delivery (SIRD)
Trial: 19919768
Drug: Isoniazid preventive
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid preventive therapy (IPT) for asymptomatic children aged <6 years
Trial: 9416380
Drug: Modified heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified heparin dosing nomogram (institution-specific)
Trial: 9416380
Drug: Physician-directed dosing
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-directed dosing
Trial: 9416380
Drug: Unmodified heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmodified heparin dosing nomogram (18 units/kg/h)
Trial: 8311278
Drug: S (+)
RxNorm normalized name: Guardian Paracetamol Extra Plus (+) (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S (+) ketamine (1 mg/kg, Group I, n = 30)
Trial: 8311278
Drug: Racemic ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic ketamine (2 mg/kg, Group II, n = 30)
Trial: 28453453
Drug: Magnetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic therapy for 50 minutes per session, two sessions per week for 4 months
Trial: 28453453
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment alone (control group)
Trial: 23182407
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg pramipexole
Trial: 18458518
Drug: Integrated symptom
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated symptom management program for 6 months (tailored education, stress management, exercise, diet, deep breathing, music therapy, periodical telephone monitoring, daily log)
Trial: 16569351
Drug: Inhaled tobramycin
RxNorm normalized name: tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled tobramycin (15 mg aerosolized, twice daily for 10 days)
Trial: 16569351
Drug: Oral amoxicillin/clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin/clavulanate (50 mg/Kg, twice daily for 10 days)
Trial: 1395889
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of aminophylline slowly
Trial: 1395889
Drug: Traditional three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional three drugs combination treatment
Trial: 24905629
Drug: Ephedrine/caffeine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine/caffeine combination (200/20 mg, n=6)
Trial: 22301417
Drug: Nevirapine (NVP)
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine (NVP) twice daily after a 14-day once-daily lead-in period
Trial: 17106838
Drug: Day hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day hospital detoxification treatment
Trial: 10086941
Drug: Budesonide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (200 microg or one puff twice daily)
Trial: 2236711
Drug: 3.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg bupivacaine 0.5%
Trial: 2236711
Drug: 7 ml
RxNorm normalized name: ethanol 7 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 ml bupivacaine 0.25%
Trial: 2236711
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml bupivacaine 0.175%
Trial: 28795506
Drug: D-4F 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-4F 300 mg
Trial: 28795506
Drug: D-4F 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-4F 500 mg
Trial: 19382472
Drug: Hydrotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrotherapy with Chinese drugs (HT‐C)
Trial: 17365264
Drug: Adalimumab (either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (either dosage)
Trial: 15479320
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA, n = 19)
Trial: 11583193
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m2 on days 1 + 8 of a three-week schedule combined with carboplatin AUC 4 on day 1
Trial: 30486656
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention combining cognitive stimulation group and tai chi (14 sessions, twice a week)
Trial: 18268065
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) + L-arginine (ARG)
Trial: 12460699
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 to 15 mg/day)
Trial: 12460699
Drug: Fosinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (10 to 30 mg/day)
Trial: 12460699
Drug: Amlodipine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine plus Fosinopril (5/10 to 15/30 mg/day)
Trial: 10554808
Drug: Granulocyte‐CSF (G‐CSF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte‐CSF (G‐CSF) + Erythropoietin (EPO)
Trial: 8533910
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg oral famotidine 3 h before induction of anesthesia
Trial: 7036291
Drug: Immunostimulation (BCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunostimulation (BCG or levamisole) with chemotherapy dimethyl ‐ triazeno ‐ imidazole ‐ carboxamide (DTIC)
Trial: 7036291
Drug: New agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New agents being screened for stage III melanoma
Trial: 25083802
Drug: Life Goals
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life Goals Collaborative Care (LG‐CC)
Trial: 12594140
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine + clonidine
Trial: 12594140
Drug: i.v. morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. morphine (control group)
Trial: 8816618
Drug: No GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No GnRH agonist (control group A)
Trial: 1609047
Drug: Haloperidol (1-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (1-3 mg daily)
Trial: 1609047
Drug: Thioridazine (25-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine (25-75 mg daily)
Trial: 16102903
Drug: LRRK 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LRRK 2 G 2019 S mutation screening in Parkinson's disease patients
Trial: 16102903
Drug: LRRK 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LRRK 2 G 2019 S mutation screening in other neurodegenerative diseases (Alzheimer's, Progressive Supranuclear Palsy, Multiple System Atrophy, frontotemporal dementia)
Trial: 12239432
Drug: Beta-carotene content
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene content in oral mucosa epithelium (OMC) in skin type I
Trial: 12239432
Drug: Beta-carotene content
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene content in oral mucosa epithelium (OMC) in skin type IV
Trial: 2390431
Drug: ICS 205-930
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS 205-930 (20 mg)
Trial: 2390431
Drug: ICS 205-930
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS 205-930 (10 mg)
Trial: 6291763
Drug: CAM combination
RxNorm normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM combination chemotherapy (cyclophosphamide, doxorubicin, and methotrexate)
Trial: 6291763
Drug: Single‐agent sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single‐agent sequential chemotherapy (cyclophosphamide, doxorubicin, and methotrexate)
Trial: 6291763
Drug: CAM combination
RxNorm normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM combination chemotherapy
Trial: 6291763
Drug: Single‐agent sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single‐agent sequential chemotherapy
Trial: 6291763
Drug: Overall survival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall survival for single-agent sequential chemotherapy
Trial: 26799573
Drug: Magnetic resonance
RxNorm normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic resonance therapy (MRT) - 10 sessions of one hour daily
Trial: 26799573
Drug: Magnetic resonance
RxNorm normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic resonance therapy (MRT)
Trial: 23093256
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg progesterone vaginal gel
Trial: 19789415
Drug: Preterax (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preterax (2 mg perindopril/0.625 mg indapamide)
Trial: 17257820
Drug: NIPSV (noninvasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIPSV (noninvasive pressure support ventilation) administered pre‐ and postoperatively for 7 days at home before surgery and 3 days postoperatively
Trial: 14982787
Drug: Intravenous dalbavancin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dalbavancin (single doses starting at 140 mg, escalating to 1120 mg; multiple doses with a 300 mg loading dose followed by six daily 30 mg maintenance doses)
Trial: 14982787
Drug: Intravenous dalbavancin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dalbavancin (various doses)
Trial: 9864778
Drug: Short-term corticosteroid
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term corticosteroid therapy (up to 21 days)
Trial: 2646350
Drug: Nicergoline, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline, 60 mg daily
Trial: 31012562
Drug: Topical test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical test product (peptide combination)
Trial: 28679486
Drug: Fibrinogen, von
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen, von Willebrand factor (vWF), tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor type 1 (PAI-1)
Trial: 25727857
Drug: Prolastin-C (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolastin-C (60 mg/kg) administered weekly over 3 years
Trial: 25727857
Drug: Prolastin-C (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolastin-C (120 mg/kg) administered weekly over 3 years
Trial: 25727857
Drug: Prolastin-C (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolastin-C (60 mg/kg) and Prolastin-C (120 mg/kg)
Trial: 23898805
Drug: Integrated Treatment
RxNorm normalized name: Bag Spike + Integrated Clave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Treatment (IT) (N=30)
Trial: 23898805
Drug: Treatment-as-Usual (TAU)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-Usual (TAU) (N=20)
Trial: 19484786
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg intravenously on Day 1)
Trial: 19484786
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no infusion during ADT)
Trial: 16967399
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of dopamine
Trial: 631013
Drug: Methadone test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone test dose pupillography
Trial: 31533751
Drug: wIRA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wIRA treatment
Trial: 31533751
Drug: no-wIRA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no-wIRA treatment (control group)
Trial: 28078599
Drug: Gatifloxacin ophthalmic
RxNorm normalized name: gatifloxacin ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin ophthalmic solution 0.3%
Trial: 25043278
Drug: Low-dose adjuvanted
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose adjuvanted sIPV
Trial: 19753300
Drug: rIFN‐gamma1b (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN‐gamma1b (both nebulized and subcutaneous)
Trial: 19753300
Drug: Subcutaneous rIFN‐gamma1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous rIFN‐gamma1b
Trial: 11163560
Drug: Heparin coating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin coating (general)
Trial: 8006914
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of quinapril and hydrochlorothiazide (HCTZ)
Trial: 8006914
Drug: Quinapril monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril monotherapy
Trial: 8006914
Drug: HCTZ monotherapy
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCTZ monotherapy
Trial: 8006914
Drug: Quinapril and
RxNorm normalized name: quinapril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril and HCTZ combination therapy
Trial: 8006914
Drug: Quinapril (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (40 mg) with HCTZ
Trial: 19516176
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tea flavonoids/day
Trial: 19516176
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tea flavonoids/day
Trial: 19516176
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg tea flavonoids/day
Trial: 19516176
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg tea flavonoids/day
Trial: 11479470
Drug: Stenting with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stenting with >=1 heparin-coated stent
Trial: 9756247
Drug: Low-energy density
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy density (LED) diet (357 kJ/100 g)
Trial: 9756247
Drug: High-energy density
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy density (HED) diet (629 kJ/100 g)
Trial: 7923965
Drug: Arginine infusion
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine infusion without captopril (group I)
Trial: 7923965
Drug: Arginine infusion
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine infusion in IgA nephropathy patients (group III)
Trial: 7923965
Drug: Arginine infusion
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine infusion in normals without captopril (group I)
Trial: 3207855
Drug: Ergoloid mesylates
RxNorm normalized name: Ergoloid Mesylates
DrugBank: Ergoloid mesylate (DB01049)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergoloid mesylates (3-9 mg) administered via oral swallow and sublingual tablets, solution, under fasted and with meal conditions.
Trial: 31628121
Drug: Broccoli sprout
RxNorm normalized name: BROCCOLI SPROUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli sprout extract (24 mg of activated sulforaphane, twice daily until delivery)
Trial: 25973838
Drug: Clipping plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clipping plus epinephrine-saline injection (group B)
Trial: 11930309
Drug: RSV immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV immunoglobulin therapy
Trial: 8564323
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) as an adjuvant to treatment as usual
Trial: 8564323
Drug: Low-dose lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose lithium therapy
Trial: 8564323
Drug: Placebo maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo maintenance therapy
Trial: 2374273
Drug: 420 kcal/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 420 kcal/d diet for 16 weeks followed by a conventional reducing diet for the remainder of treatment
Trial: 949108
Drug: Etomidate infusion
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etomidate infusion (2.55 mg/kg)